Assessing the quality of reporting in artificial intelligence/machine learning research for cardiac amyloidosis.

ABSTRACT:

Objectives

Despite the rapid development of AI in clinical medicine, reproducibility and methodological limitations hinder its clinical utility. In response, MINimum Information for Medical AI Reporting (MINIMAR) standards were introduced to enhance publication standards and reduce bias, but their application remains unexplored. In this review, we sought to assesses the quality of reporting in AI/ML studies of cardiac amyloidosis (CA) an increasingly important cause of heart failure.

Materials and methods

Using PRISMA-ScR guidelines, we performed a scoping review of English-language articles published through May 2023 which applied AI/ML techniques to diagnose or predict CA. Non-CA studies and those with selective feature sets were excluded. Two researchers independently scr

SUBMITTER: Arefeen A 

PROVIDER: S-EPMC12507469 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature